Elisa Izquierdo Delgado

Abstract CD19-CAR-T cells are a major therapy for relapsed/refractory B-cell malignancies, yet ~50% of patients relapse after infusion. Clinical data suggest that tisa-cel treatment is associated with higher rates of CD19 mutation than axi-cel, though direct comparisons have been lacking. Although both products target the FMC63 epitope, they employ different structures of hinge/transmembrane/costimulatory domains (CD8α/CD8α/4-1BB in tisa-cel, CD28/CD28/CD28 in axi-cel).

David Martínez-Duncke [1] ; Agustín Ramiro Urzúa-González [2] ; Luisa Fernanda Aguilera-Mora [3] ; José S Laínez-Zelaya [4] ; Jorge Álvarez de la Cadena-Sillas [5] ; Manuel de Jesús Celaya-Cota [6] ; Erik H González-Cruz [7] ; Elisa Delgado [7] ; Ismael Campos-Nonato [8] ; Edgar Denova-Gutiérrez [8] ; Aurelio Cruz-Valdez [9] ; Jorge Eduardo Cossio-Aranda [10] ; Arturo Guerra-López [10] ; José Manuel Enciso-Muñoz [11] ; Luis Daniel Sánchez-Arreola [12] ; José Antonio Magaña-Serrano [13] ;...

One of the most widely used ways to preserve and archive clinical specimens is the preparation of formalin-fixed, paraffin-embedded (FFPE) samples. Such archived specimens represent a valuable source of tissue for molecular studies. However, ensuring good-quality genetic sequencing data from DNA that has been extracted from FFPE specimens can be challenging due to both quality and quantity issues (see Figure 1).